Age and outcome after acute coronary syndromes without persistent ST-segment elevation

Background Although age is the most important variable associated with death among patients with presistent ST-segment elevation, its impact an outcome among patients without persistent ST-segment elevation remains unknown. Moreover, the impact of age on the efficacy of antiplatelet therapy with eptifibatide is unknown. Methods We analyzed the impact of increased age on outcome (death or [re]infarction) among patients enrolled in PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy), a prospective, randomized study comparing placebo versus eptifibatide therapy in acute coronary syndromes without persistent ST-segment elevation. The 9461 patients were divided into 10-year age groups: <50, 50–59, 60–69, 70–79, and ≥80. In addition, we examined whether age had an impact on the efficacy of eptifibatide therapy. Results Eptifibatide improved outcome at 30 days (P= .04). There was no interaction among age and treatment (placebo vs eptifibatide) and adjusted outcome (P = .16 for death or [re]infarction at 30 days). Despite their worse clinical profile, older patients were less likely to undergo coronary angiography at 30 days: 936 (71%), 1489(68%), 1969 (65%), 1357 (57%), and 193 (38%) in the respective age groups. Death or [re]infarction at 30 days occurred in 121 (9%), 255 (12%), 447 (15%), 460 (19%), and 134 (26%) in the respective age groups, and at 6 months in 149 (11%), 301 (14%), 547 (18%), 575 (24%), and 162 (32%). For a 10-year difference in age group, the adjusted odds for death or [re]infarction were greater by 33% within the 30 days and by 34% within 6 months. These trends persisted for patients with or without myocardial infarction on presentation. Conclusions Age did not significantly affect the efficacy of eptifibatide. Older age among patients with acute coronary syndromes was associated with worse baseline characteristics, fewer invasive procedures, and worse outcome.